Close
Virtual Symposium: Lessons from COVID-19 Part 2 – Impact on palliative care

Virtual Symposium: Lessons from COVID-19 Part 2 – Impact on palliative care

Reading Time: 4 minutes This is the second in a series of three blog articles from Session 7 – Perspectives: Lessons from COVID-19 in which we heard from different speakers about how the COVID-19 pandemic has impacted their own experiences of clinical trials, research, and support within the MND community. A further blog, written by Bruce Virgo who is…

Virtual Symposium: Lessons from COVID-19 Part 1 – Impact on clinical trials

Virtual Symposium: Lessons from COVID-19 Part 1 – Impact on clinical trials

Reading Time: 3 minutes This is the first in a series of three blog articles from Session 7 – Perspectives: Lessons from COVID-19 in which we heard from different speakers about how the COVID-19 pandemic has impacted their own experiences of clinical trials, research, and support within the MND community. A further blog, written by Bruce Virgo who is…

Virtual Symposium: Update on AMX0035 CENTAUR and open-label extension trials

Virtual Symposium: Update on AMX0035 CENTAUR and open-label extension trials

Reading Time: 5 minutes This blog is part of the ‘Virtual Highlights’ collection of articles, where you can read about the content of some of the talks and posters presented at the Virtual 31st International Symposium on ALS/MND. This presentation was part of Session 3: Clinical Trials. Presented by Dr Sabrina Paganoni, from the Sean M. Healey & AMG…

Virtual Symposium: Phase 3 clinical trial results – levosimendan

Virtual Symposium: Phase 3 clinical trial results – levosimendan

Reading Time: 2 minutes This blog is part of the ‘Virtual Highlights’ collection of articles, where you can read about the content of some of the talks and posters presented at the Virtual 31st International Symposium on ALS/MND. This presentation was part of Session 3: Clinical Trials. Presented by Dr Merit Cudkowicz, from Harvard Medical School and Massachusetts General Hospital,…

Virtual Symposium: Results from the Phase 3 clinical trial of NurOwn

Virtual Symposium: Results from the Phase 3 clinical trial of NurOwn

Reading Time: 4 minutes This blog is part of the ‘Virtual Highlights’ collection of articles, where you can read about the content of some of the talks and posters presented at the Virtual 31st International Symposium on ALS/MND. This presentation was part of Session 3: Clinical Trials Co-presented by Dr Merit Cudkowicz, from Harvard Medical School and Massachusetts General…

ALS reversals – do they exist?

ALS reversals – do they exist?

Reading Time: 6 minutes In July 2020 Everything ALS, a team of patient advocates, medical professionals, entrepreneurs, computational biologists and medical students based in the USA, hosted a virtual discussion and Q&A session with Dr Richard Bedlack, Professor of Neurology at Duke University in California, in which he discussed his unique perspective on ALS reversals. Dr Bedlack claims to…

Highlighting MND researchers of the future – part 2

Highlighting MND researchers of the future – part 2

Reading Time: 4 minutes Last week saw the culmination of 12-months of planning as the 30th International Symposium on ALS/MND took place in Perth, Australia. The Symposium brings together the brightest minds from the MND research and healthcare communities. With 100 oral presentations, and over 420 posters, the Symposium is an opportunity for around 1,000 researchers and healthcare professionals…